These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9873590)

  • 1. Synthesis and properties of prodrugs activated in hypoxia to give bleomycin analogues.
    Highfield JA; Mehta LK; Parrick J; Candeias LP; Wardman P
    Bioorg Med Chem Lett; 1998 Sep; 8(18):2609-14. PubMed ID: 9873590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, hydroxyl radical production and cytotoxicity of analogues of bleomycin.
    Highfield JA; Mehta LK; Parrick J; Wardman P
    Bioorg Med Chem; 2000 May; 8(5):1065-73. PubMed ID: 10882018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.
    Hay MP; Denny WA; Wilson WR
    Anticancer Drug Des; 1996 Jul; 11(5):383-402. PubMed ID: 8765531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.
    Thomson P; Naylor MA; Everett SA; Stratford MR; Lewis G; Hill S; Patel KB; Wardman P; Davis PD
    Mol Cancer Ther; 2006 Nov; 5(11):2886-94. PubMed ID: 17121936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-Activated Prodrugs of PERK Inhibitors.
    Liew LP; Singleton DC; Wong WW; Cheng GJ; Jamieson SMF; Hay MP
    Chem Asian J; 2019 Apr; 14(8):1238-1248. PubMed ID: 30615821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward targeted "oxidation therapy" of cancer: peroxidase-catalysed cytotoxicity of indole-3-acetic acids.
    Folkes LK; Candeias LP; Wardman P
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):917-20. PubMed ID: 9845122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs.
    Dragovich PS; Broccatelli F; Chen J; Fan P; Le H; Mao W; Pillow TH; Polson AG; Wai J; Xu Z; Yao H; Zhang D
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5300-5304. PubMed ID: 29079474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The design, synthesis and evaluation of hypoxia-activated pro-oligonucleotides.
    Zhang N; Tan C; Cai P; Zhang P; Zhao Y; Jiang Y
    Chem Commun (Camb); 2009 Jun; (22):3216-8. PubMed ID: 19587918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxygen transfer reactions by synthetic analogues of iron-bleomycin.
    Dawson DY; Hudson SE; Mascharak PK
    J Inorg Biochem; 1992 Aug; 47(2):109-17. PubMed ID: 1279119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminoferrocene-based prodrugs activated by reactive oxygen species.
    Hagen H; Marzenell P; Jentzsch E; Wenz F; Veldwijk MR; Mokhir A
    J Med Chem; 2012 Jan; 55(2):924-34. PubMed ID: 22185340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitro seco analogues of the duocarmycins containing sulfonate leaving groups as hypoxia-activated prodrugs for cancer therapy.
    Stevenson RJ; Denny WA; Tercel M; Pruijn FB; Ashoorzadeh A
    J Med Chem; 2012 Mar; 55(6):2780-802. PubMed ID: 22339090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.
    Urquiola C; Vieites M; Torre MH; Cabrera M; Lavaggi ML; Cerecetto H; González M; Cerain AL; Monge A; Smircich P; Garat B; Gambino D
    Bioorg Med Chem; 2009 Feb; 17(4):1623-9. PubMed ID: 19162490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The production of hydroxyl radical from copper(I) complex systems of bleomycin and tallysomycin: comparison with copper(II) and iron(II) systems.
    Sugiura Y
    Biochem Biophys Res Commun; 1979 Sep; 90(1):375-83. PubMed ID: 91372
    [No Abstract]   [Full Text] [Related]  

  • 14. Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones.
    Jaffar M; Everett SA; Naylor MA; Moore SG; Ulhaq S; Patel KB; Stratford MR; Nolan J; Wardman P; Stratford IJ
    Bioorg Med Chem Lett; 1999 Jan; 9(1):113-8. PubMed ID: 9990467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
    Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
    J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
    Tercel M; Atwell GJ; Yang S; Stevenson RJ; Botting KJ; Boyd M; Smith E; Anderson RF; Denny WA; Wilson WR; Pruijn FB
    J Med Chem; 2009 Nov; 52(22):7258-72. PubMed ID: 19877646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of p-phenylenediamine with the iron-bleomycin complex.
    Løvstad RA
    Biometals; 1999 Sep; 12(3):233-6. PubMed ID: 10581686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Models of hypoxia activated prodrugs: Co(III) complexes of hydroxamic acids.
    Failes TW; Hambley TW
    Dalton Trans; 2006 Apr; (15):1895-901. PubMed ID: 16585977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
    Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
    J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters.
    Lin YS; Tungpradit R; Sinchaikul S; An FM; Liu DZ; Phutrakul S; Chen ST
    J Med Chem; 2008 Dec; 51(23):7428-41. PubMed ID: 19053781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.